Pricing Log in Create free account

Moolec Science SA (MLEC) vs NexImmune, Inc. (NEXI)

Moolec Science SA and NexImmune, Inc. are both Biotechnology companies. NexImmune, Inc. is the larger, with a market value of $1.6M against $1.4M — 1.2× the size. NexImmune, Inc. has the higher net margin (0.00% vs −7.18%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Moolec Science SA leads on 6 and NexImmune, Inc. on 5.

Valuation

Metric MLEC NEXI Biotechnology median
P/E n/m n/m 8.50
P/S 0.00 n/m 9.71
P/B 0.03 n/m 2.13
Price to free cash flow 0.02 n/m 20.82
EV/EBITDA 1.76 n/m 0.64
EV/Sales 0.14 n/m 9.21
Earnings yield (4,665.32%) 0.00% (33.15%)
Free cash flow yield 4,200.26% 0.00% (25.50%)

Profitability

Metric MLEC NEXI Biotechnology median
Gross margin 39.67% 0.00% 65.16%
Operating margin 4.09% 0.00% 0.00%
Net margin (7.18%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (232.97%) (56.36%)
Return on assets 0.00% (140.56%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLEC NEXI Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (447.53%) 52.58% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLEC NEXI Biotechnology median
Debt to equity 4.37 0.00 0.00
Current ratio 0.15 0.66 4.72
Net debt to EBITDA (2.73) 0.10 0.96

Dividend

Metric MLEC NEXI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MLEC NEXI Biotechnology median
Market cap 1.36m 1.60m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack